US mRNA specialist Moderna has reported first-quarter revenues of $1.86 billion.
This represents a fraction of the $5.93 billion reported in the same period last year, due to an inevitable decline in demand for Moderna’s SpikeVax COVID-19 vaccine, the company’s old on-market product.
But the revenue figure still exceeded the $1.18 billion expected by analysts, based on a survey by Refinitiv.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze